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Abstract
Background: Informed consent is a key element of ethical clinical research. Addicted population may be at risk for
impaired consent capacity. However, very little research has focused on their comprehension of consent forms. The
aim of this study is to assess the capacity of addicted individuals to provide consent to research.
Methods: 53 subjects with DSM-5 diagnoses of a Substance Use Disorder (SUD) and 50 non psychiatric comparison
subjects (NPCs) participated in the survey from December 2014 to March 2015. This cross-sectional study was
carried out at a community-based Outpatient Treatment Center and at an urban-located Health Centre in Spain. A
binary judgment of capacity/incapacity was made guided by the MacArthur Competence Assessment Tool for
Clinical Research (MacCAT–CR) and a clinical interview. Demographics and clinical characteristics were assessed by
cases notes and the Mini-Mental State Examination, the Global Assessment Functional Scale and the Clinical Global
Impression Scale.
Results: NPCs performed the best on the MacCAT–CR, and patients with SUD had the worst performance,
particularly on the Understanding and Appreciation subscales. 32.7 % SUD people lacked research-related decisional
capacity. There were no statistically significant differences between the groups in terms of capacity to consent to
research.
Conclusions: The findings of our study provide evidence that a large proportion of individuals with SUD had
decisional capacity for consent to research. It is therefore inappropriate to draw conclusions about capacity to make
research decisions on the basis of a SUD diagnosis. In the absence of advanced cognitive impairment, acute
withdrawal or intoxication, we should assume that addicted persons possess decision-making capacity. Thus, the
view that people with SUD would ipso facto lose decision-making power for research consent is flawed and
stigmatizing.
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Background
Obtaining informed consent is a cornerstone of biomed-
ical research. It constitutes a fundamental ethical require-
ment that is given priority in all national and international
research ethics codes [1, 2]. Valid informed consent re-
quires the researcher to ensure that the consent provided
is voluntary and the patient is competent to make the de-
cision [3]. The standard informed consent process of
requiring a routine signature on a document does not en-
sure fully shared decision-making [4], it’s necessary to as-
sess the capacity of research participants to provide
meaningful consent prior to entry into clinical trials.
In Spain, there are no defined guidelines as to who
should assess patient decision-making competence or
how such assessments should be accomplished. Spanish
laws about informed consent in biomedical research
touch upon a subject's decision-making capacity and in-
dicate those situations where the capacity is limited
without defining or specifying how it should be assessed
[5, 6]. Laws emphasise the necessity of justifying the
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inclusion of “vulnerable populations” in research, with-
out specifying who these vulnerable populations are [7].
There are no specific regulations concerning the re-
search participation of patients with psychiatric or ad-
dictive disorders. Proxy consent in research will be
necessary if (a) persons are younger than 18 years of age
(except for emancipated minors who are regarded as
capable of making decisions); (b) the physician respon-
sible ascertains that the patient's ability to take part in
the decision-making process is impaired; or (c) the pa-
tient is legally incompetent [5, 6]. A person is considered
legally incompetent if he is unable to understand or
communicate information to meet essential requirements
of physical health, safety or property management. In
Spain, the courts are responsible for determining the legal
competence of an individual basing their judgement on
two medical reports.
As defined in psychiatric classifications, addiction is a
disorder in which an individual’s control over their drug
use is impaired [8]. People with an addiction continue to
use drugs in the face of enormous negative conse-
quences, and despite often expressing a wish that they
could stop. This perspective is codified in the diagnostic
criteria for addiction, in which a loss of control over
drug use is central and becomes compulsive-something
engaged in at the expense of all other goal-directed ac-
tivities such as work or relationships [8]. Concerns have
been raised about the capacity and voluntariness of
people with SUD to participate in research. Some ethicts
and clinicians have interpreted the DSM-5 criteria that
describe loss of control and compulsive behavior in ab-
solute terms [9, 10]. They argued that people with SUD
fail to satisfy the required standards for competent vol-
untary consent and that we should assume that addicts
are incompetent to consent to trials unless proven other-
wise. Besides these caveats, there are other factors that
can affect the ability of addicted individuals to provide
consent to research because of the direct effects of their
substance abuse as well as a wide range of co-morbid
conditions. Acute drug intoxication or withdrawal may
impair attention or retention of important information.
Limited educational opportunities, chronic brain changes
resulting from long-term drug use, poor nutrition, and co-
morbid health problems are common in individuals with
SUD and may also reduce concentration and limit under-
standing during the informed consent process [11].
Given the enormous health, economic and social bur-
dens arising from SUD, there is strong public interest in
preventing drug use [12]. The Demand Reduction Sec-
tion of the United Nations International Drug Control
Programme covers actions focusing in treatment and
prevention, demand and supply reduction, international
cooperation, training and improvement of scientific
knowledge about SUD [13]. The Spanish National Drug
Strategy 2009–2016 [14] is closely linked to the actions
arising from the European Union and the United Na-
tions (UN). The Spanish government has long coopera-
ted in the policy and decision making bodies within the
UN system, by providing technical assistance and fund-
ing for projects executed by bodies specializing in drugs
[14]. Research in this field will lead to develop more ef-
fective treatments that will reduce the harm caused to
the individual and society. Addicted individuals arguably
have the same right to participate in, and benefit from,
scientist research into their condition as anyone afflicted
by any other disorder [15]. The potential personal, social
and scientific benefits of neuroscience research of addic-
tion, however, are not sufficient to justify research if it ex-
ploits a vulnerable population [16]. We need to show that
those participating in such research are capable of consent-
ing freely, that consent is obtained in ways that respects
their autonomy, and that there is an acceptable balance of
risk and benefit to addicted research participants.
For all these reasons the capacity assesment in
addicted people becomes so important. The available
data on decisional capacity among persons suffering
from SUD are meager; very little research has focused
on their comprehension of consent forms [17–19].
There is a need for studies of decisional capacity for
consent to research among people with SUD, using stan-
dardized instruments [19]. Although there is no “gold
standard” method for assessing capacity, the MacArthur
Competence Assessment Tool for Clinical Research
(MacCAT-CR) appears to be the single most widely used
instrument for formal assessment of capacity to consent
to research [20].
In 2013, a Spanish translation of the MacCAT-CR was
made available by Baon [21] and in 2014; a manual was
published to provide the assessing clinicians or re-
searchers a structured method to aid them in the IC
procedure [22]. However its use isn’t extended yet and
evaluations of a patient’s decision-making competence
are still based on intituive assesments.
The aim of the present study is to asses the capacity of
addicted individuals to provide consent to research by
means of the recent Spanish version of the MacCAT-CR.
Methods
Type of study
We conducted a cross-sectional survey, which was ap-
proved by the ethical research committee of Sta María del
Rosell Hospital in Cartagena, Health Service of Murcia.
Participants
Participants were 53 individuals seeking treatment for al-
cohol and/or illicit substance use at a community-based
Outpatient Treatment Center and 50 non psychiatric
comparison subjects (NPCs) from an urban-located
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health centre. The study was carried out over a 4-month
period (From December 2014 to March 2015) in south-
eastern Spain. Every consecutively referred or identified
patient meeting the inclusion criteria was invited to par-
ticipate. Participants included outpatients with DSM-5
diagnoses of SUD and NPCs diagnosed of hypertension,
diabetes mellitus or other mild medical illnesses. Inclu-
sion criteria were (a) currently 18 years or older, (b)
diagnosis matching targeted conditions, (c) fluency in
Spanish, (d) current score on the Spanish version of the
Mini-Mental State Examination: (MMSE) 20 or higher
[23], and (e) voluntary informed consent to participate
in this study.
NPCs were excluded if (a) they met criteria for a
DSM-5 current SUD or other Axis I diagnoses, (b) they
were active patients at Mental Health Centre or at Cen-
ter for Substance Abuse Treatment and (c) they were in
psychiatric treatment with their General Practitioner.
Substance abusers were excluded if they were intoxi-
cated or suffering acute withdrawal symptoms at the
time when consent is requested.
Measures
Patient information was collected through the use of a
questionnaire designed to obtain data on variables re-
garding patient demographics and clinical characteris-
tics. Level of functioning was evaluated using the Global
Assessment Functional Scale (GAF) (addict subjects
only), [24] and severity of symptoms was assessed using
the Clinical Global Impression Scale (CGI) (addict sub-
jects only) [25].
Judgments on mental capacity were based on a clinical
assessment (review of notes and clinical interview) and
the administration of the Spanish version of the
MacCAT-CR [21]. This instrument is a semistructured
interview adapted to the elements of a specific research
protocol and it evaluates the 4 commonly recognized di-
mensions of decisional capacity: (a) understanding the
relevant information; (b) appreciation of the effects of
research participation on the patient’s own situation; (c)
reasoning with the information in a decisional process
and (d) expressing a choice about participation [20].
MacCAT-CR administration involves disclosure of infor-
mation about the study that subjects are being asked to
consider, in this case a hypothetical medication trial de-
signed by ourselves, followed by questions that assess
the four dimensions of decisional capacity. Each ability
is assessed by specific questions with answers rated on a
0–2 scale with higher scores reflecting better perform-
ance. The understanding scale has thirteen questions
(range 0–26), the appreciation scale has three questions
(range 0–6), the reasoning scale has four questions
(range 0–8) and the expressing a choice scale has only
one question (range 0–2). This instrument has been
widely used in research and is described in detail else-
where [20, 26].
The MacCAT-CR does not yield a limit score on the
four abilities, but for practical purposes in some studies,
cut-points have been determined to identify those who
lack capacity [26–29]. Previous studies in populations
with dementia or psychiatric disorders have demon-
strated a high degree of reliability [30] and indications of
validity [21, 31]. An Understanding score of 20 or higher
on the 26-point scale was required as a minimum for be-
ing capable, according to the study of Carpenter al-
though clinical judgment was the final determinant of
competence to consent even if a subject achieved this
threshold [26]. This threshold reflected an a priori judg-
ment by the investigators of what constituted minimally
adequate understanding of this specific research proto-
col. The understanding scale was used to establish the
threshold of capacity because understanding generally
correlates highly with appreciation and moderately with
reasoning, and has the strongest psychometric properties
of the three scales [32].
Procedures
We used an interactive consent process to ensure ad-
equate understanding of the protocol basics. A research
assistant met with the potential participants (together
with their legal guardians if they were legally incompe-
tent) and gave them both verbal and written information
about the study. Cognitive state was evaluated by using
the MMSE excluding those patients with advanced cog-
nitive impairment. The research assistant reviewed the
information in the consent form with the potential par-
ticipants, and then, written informed consent was ob-
tained from all patients and from legal guardian if the
participant was legally incompetent. No subject was le-
gally incompetent, so this surrogate consent procedure
wasn’t necessary.
Within one month following the initial assessment,
two trained research assistants conducted all the cap-
acity evaluations. Research technicians were trained by
the research coordinator to administer the MacCAT-CR
in a scripted and highly standardized manner. The re-
search coordinator conducted multiple role plays of the
consent process with the research technicians until they
had successfully mastered the process.
We developed a hypothetical consent form describing
a randomized controlled trial of an experimental com-
pound (which we named “Semoca”) being tested for
hedeache, which was modeled after phase II studies of
similar agents. The consent form described a 16-week
randomized comparison of Semoca vs placebo. It was 5
doubled-spaced pages and had a Flesch-Kincaid reading
level of 13, the reading level generally suggested in the
literature [33]. Procedures described to the patients
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included randomized assignment, blinded exposure to a
new tablet, the voluntary nature of participation, proce-
dures for withdrawal from the study and risks (blood
draw and non-life-threatening side effects of the drug).
The inability to guarantee direct benefit was explained
as well. Each subject read this hypothethical project
aloud and then, the MacCAT–CR was administered. We
stopped the interview if there was any change in choice,
or resistance. Only one patient was lost.
After each interview, the researcher scored the four
subscales according to MacCAT–CR criteria. The inter-
views weren’t videotaped but there was a verbatim tran-
scription because the investigators interviewed the
subjects with other co investigator present who took
notes. Later on, these transcribed interviews were inde-
pendently reviewed by two people (a medical ethics spe-
cialist and a psychiatrist) each of whom assigned their
own scores to each patient based on the MacCAT-CR
rating guidelines. A consensus meeting was then held to
derive a single score for each case when the judgment
was felt to be difficult. In practice this amounted to
seven interviews. The research team made a global judge-
ment about the patient’s capacity to consent to research,
based on information from both the MacCAT–CR and
the clinical interview with the patient. The investigators
met regularly with I.M.S. and M.D.P.C. to review and dis-
cuss any scoring questions.
Data analysis
Data were analyzed with SPSS (version 19.0). Prior to
analysis, all data was examined for normality and homo-
geneity of variance. Differences between groups on
ordinal or continuous data were analyzed using the two-
sample parametric t test/1-way analyses of variance and
the Mann–Whitney U test/ Kruskal- Wallis test for non
parametric data. Group differences in categorical vari-
ables were compared with using Pearson’s χ2 or Fisher’s
exact test for non parametric data.
To examine the relationship between the independent
and dependent variables, we calculated the odds ratios
(ORs) and 95 % CIs. Multivariate analyses with logistic
regression were carried out with the variables that
showed a significant relation with the dependent variable
in the univariate analyses and were clinically relevant.
To avoid an overfit model we followed the rule which
states that for every independent variable, there should
be no fewer than 10 events per covariate [34]. Then, by
direct selection, we obtained a model with the individual
variables directly related to the dependent variable (lack
of capacity). To assess model’s overall fit to the sample
data we used the Hosmer-Lemeshow goodness-of-it test.
It produced a high p-value so our model passed the test
and the difference between observed and model-
predicted values was small. Colinearity tests were carried
out between explanatory variables, calculating the vari-
ance inflation factor (VIF) for each. This gave a value of
VIF < 3 for each variable, so colinearity was rejected,
meaning that the possibility of overfitting was minimal.
A probability level of p ≤ 0.05 (two tailed) was consid-
ered significant.
Results
Demographic and clinical characteristics
Of the 205 subjects eligible for this study, 103 were ex-
cluded or were unavailable to participate for various rea-
sons (Fig. 1).
The SUD group was the youngest 42.9 ± 11.9 years (p
< .001). The proportion of women was highest among
NPCs 62.0 % (n = 31) vs 28.3 % (n = 15) (p < .001). Most
NPCs 88 % (n = 41) were married whilst 67.9 % (n = 36)
SUD people have never married or have been previously
married (p < .001). 88 % NPCs (n = 41) live with their
family and none live in an institution while 45.3 % SUD
people (n = 24) live with their families and 39.6 % (n =
21) with their parents or in an institution (p < .001). The
patients with SUD had fewer years of education than
those in the other group (p < .001), only 9.4 % SUD
people (n = 5) completed university degree vs 40 % NPCs
(n = 20). Most of NPC were working 84 % (n = 42) vs
20.8 % (n = 11) SUD people (p < .001). The SUD group
had the most severe cognitive deficits, lowest mean
MMSE total score, 28.2 ± 4.2 points (p < .001).
Baseline characteristics of each SUD group are de-
scribed in Table 1. The 53 patients with SUD had the fol-
lowing diagnoses: 45.3 % (n = 24) had and alcohol or
cannabis use disorder, 18.9 % (n = 10) had a cocaine use
disorder and 35.8 % (n = 19) used alcohol and other drug.
Decisional capacity characteristics
Decisional capacity characteristics of each group are de-
scribed in Table 2.
On the MacCAT-CR subscales patients with SUD gar-
nered the lowest scores, particularly on the Understand-
ing and Appreciation subscales: 20.1 ± 5.2 (p < .001) and
5 ± 1.4 (p = 0.03) points respectively.
Differences on MacCAT-CR subscales scores within
each SUD group are illustrated in Fig. 2. There were no
statistically significant differences between the groups.
Ratings and factors linked with incapacity
32.69 % of the patients (n = 17), lacked research-related
decisional capacity, based on a judgement guided by the
MacCAT–CR and a clinical interview.
Socio-demographic and clinical and decisional capacity
characteristics of patients with and without mental cap-
acity are shown in Table 3.
The relationships between patients characteristics and
lack of capacity are the following: using male gender as a
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reference, the OR of lack of capacity was 4.43 (IC95%:
1.27-8.52; p = 0.044) for the women of our study. Thus,
in our sample, men seemed to be more likely to lack
capacity than female patients. Each one-point increase in
the MMSE score increased the chance of being capable
by approximately 6 %: OR = 0.60 (IC95%: 0.39-0.93; p =
0.02).
The logistic regression model included relevant vari-
ables that were significantly associated with lack of cap-
acity on univariate analysis. We choose MMSE scores by
its statistical performance and because impaired cogni-
tion is well-recognized as a limitation to the research
participation. Gender was selected by its apparent high
OR. Only one of the two variables included in the uni-
variate analysis was retained in the multivariate model:
the MMSE scores: OR = 0.602 (IC95%: 0.38– 0.95; p =
0.029).
When other variables associated with lack of capacity
on our univariate analysis are considered, gender no lon-
ger has an impact on the probability of being capable
OR = 4.36 (IC95%: 0.81-8.06; p = 0.86).
Discussion
We believe this study to be important because is the first
one that specifically assess the capacity to provide con-
sent to research among people with SUD by means of a
standardized instrument such as the MacCAT-CR. Most
people diagnosed of SUD in our survey were able to pro-
vide consent to research, we didn’t find statistically
significant differences between NPCs and SUD groups in
terms of capacity to consent to research.
Patients with SUD showed the worst performance on
the measures of the MacCAT-CR, especially in the Un-
derstanding and Appreciation dimensions. Given the
contextual nature of decisional capacity, as well as the
characteristics of the MacCAT-CR interview, a compari-
son of results across studies is somewhat difficult. The
scale does not provide cut-off scores nor is there an al-
gorithm for categorical determinations of capacity or in-
capacity. General consensus exists that as the degree of
risk increases, a higher level of capacity is desirable. This
is appropriate, as studies vary in level of risk and in the
risk/benefit ratio. Therefore, there is not a particular
level of ability which represents adequate capacity in all
circumstances [35]. Mean levels of MacCAT-CR scores
vary widely within different disorders. The mean Under-
standing total score in our SUD group was 20.1 points;
and 5.0 points on the Reasoning dimension. We didn’t
find previous research about SUD and MacCAT-CR per-
formance to compare with. Our findings will have to be
explored in future studies.
There is much variability in addicted individuals’re-
sponse to drugs and the degree of impairment they ex-
perience. As literature suggests, impairment may differ
depending on the type of drug being abused, the route
of administration, the severity of the addiction, the level
of tolerance, and the amount of time since last drug use
[12, 36]. Unexpectedly, we didn’t find significant
52 Patients 
completed the study
50 NPCs completed 
the study
92 Eligible SUD 
patients
113 Eligible NPCs
58 Enrolled/consent 53 Enrolled/consent
34 Excluded or declined
10 Chose not to participate
1  Too young
5  Mental disabled
2  Did not speak fluent 
Spanish
3  Scored < 20 in MMSE
13 Were intoxicated
60 Excluded or declined
15 Chose not to participate
5  Too young
3   Did not speak fluent Spanish
1   Scored < 20 in MMSE
29 Were in psychiatric treatment 
7   Fulfilled SUD DSM-5 criteria
6 Unavailable
5 Lost to follow up
1 Did not finished 
the   MacCAT-CR
3 Lost to follow up
Fig. 1 Flowchart of participant’s inclusion. Abbreviations: SUD, Substance use disorders; NPCs, Non psychiatric comparisons
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differences between SUD groups in our study in terms
of lack of capacity. The limited number of patients in-
cluded in each SUD group could be one explanation for
these results.
A non- abstinent drug-dependent individual can spend
significant time between periods of acute intoxication and
withdrawal in which they are not severely cognitive im-
paired. Addiction may therefore only affect addicted
individuals’ability to consent to research in some individ-
uals and in some situations. This impairment is not abso-
lute, and is not seen in all individuals in all circumstances
at all times. It is unwise to assume that decision-making in
addicted persons is so impaired to eliminate autonomy
[18].
In the present study we found an association between
education level and mental capacity. This may be due to
Table 1 Baseline characteristics of each SUD group
Variable Alcohol THC Cocaine Alcohol + other P Value
(n = 12) (n = 12) (n = 10) (n = 19)
Age, years ( mean ± SD) 51.7 (7.6) 32.9 (12.7) 43 (10.8) 43.6 (9.7) .003b
Women. (%) 33.3 25.0 20.0 31.6 .201a
Marital Status (%)
Married/cohabiting 33.3 25.0 30.0 36.8 .708a
Never married 41.7 58.3 50.0 36.9
Previous married 25.0 16.7 20.0 26.3
Living status (%) .469a
Alone 25.0 8.3 0.0 21.1
With family 50.0 41.7 40.0 47.3
Parents/institution 25.0 50.0 60.0 31.6
Education level (%) .975a
Primary 58.3 50.0 70.0 57.9
Secondary 33.3 41.7 20.0 31.6
University degree 8.3 8.3 10.0 10.5
Employment status (%) .540a
Employed 25.0 8.3 0.0 36.8
Unemployed 41.7 50.0 50.0 42.1
Retired 16.7 16.7 20.0 5.26
Disabled person 16.7 25.0 30.0 10.5
Psychiatric diagnosis (%) .080 a
Psychotic disorders 0 33.3 20 15.8
Mood Disorders 50 16.7 10 26.3
Anxiety disorders 25 50 20 31.6
No psychiatric diagnosis 25 0 50 26.3
CGI (%) .926a
Less than moderately ill 16.7 25.0 20.0 26.3
Moderately ill or more 83.3 75.0 80.0 73.7
GAF (range, 0–100) ( mean ± SD) 65.8 (12.8) 66.3 (19.2) 64.4. (14.8) 67.6 (15.9) .879b
Length of illness, years( mean ± SD) 19.7 (13.3) 7.4 (7.1) 9.8 (6.6) 18.1 (9.1) .004b
Psychiatric Admissions (mean ± SD) 0.6 (0.8) 0.7 (1.4) 0.6 (0.8) 1.7 (3.4) .995b
Therapeutic Community Admisisons (mean ± SD) 0.25 (0.4) 0.08 (0.3) 1.1 (1.5) 0.37 (0.6) .106 b
MMSE (range, 0–30) ( mean ± SD) 28.5 (1.6) 27.0 (8.5) 29.0 (1.5) 28.4 (1.6) .765b
Abbreviations: SUD, Substance use disorder; THC, Tetra hidro cannabinol; SD, standard deviation; CGI, Clinical Global Impression; GAF, Global Assessment of
Functioning; MMSE, Mini-Mental State Examination.
a Pearson’s χ2
b Mann–Whitney U
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some factors such us cognitive decline [37]. The chronic
use of addictive drugs can cause significant cognitive
deficits that may impair an addicted person’s capacity to
provide informed consent. Yet while comparison of ab-
solute levels across studies is difficult, the importance of
cognitive functions in a decisional capacity is a very con-
sistent finding across multiple disorders [37].
Our findings indicate that men were more likely to
lack capacity than female patients. Although gender gen-
erally has little demonstrable influence on cognitive
tasks [38], we don’t know specific studies about the in-
fluence of gender in research- decision-making capacity.
One study examined the level of performance of women
with major depression on the decision-making abilities
assessed by the MacCAT-CR but they didn’t include
male participants to compare the scores with [39]. In
our study when the other variables associated with in-
capacity on the multivariate analysis are considered, gen-
der has no longer a significant impact on the probability
of being capable.
Mental capacity is also univariately associated in our
study with living status. People who live with their par-
ents or in an institution were more likely to lack capacity
than those who live alone or with their families,
although we didn’t confirm this association in the logis-
tic regression model. As literature suggests, living status
may be linked to lack of capacity: given that the level of
functionality corresponds to competence, is it possible
that living alone reflects functionality [40]. The chronic
use of drugs can cause significant cognitive deficits that
may impair addicted people’s capacity to take care of
themselves or to live by their own so is more difficult for
people with SUD to achieve emancipation.
Most patients in our study have also a psychiatric dis-
order. In Spanish substance misuse services up to 70 %
of patients have co-morbid psychiatric disorders
[41].These patients with dual diagnosis may have dual
deficits in decisional capacity— compounded by im-
paired response to short-term versus long-term gains
and losses and those secondary to cognitive impairment
associated with psychiatric disorders that can influence
the decisional process [19]. However, we didn’t find sig-
nificant differences between patients with and without
dual diagnoses in our study in terms of lack of capacity.
These results will have to be explored in further research.
Symptom severity, as measured by GAF and CGI
scores was associated with lack of capacity in this re-
search. Our findings suggest that the dual diagnosis se-
verity, as measured by lower social functioning may be a
factor in the decisional process.
Only one of the considered variables remained inde-
pendently associated with incapacity on multivariate
analysis: the cognitive state. These results indicate that
cognition must be considered in capacity assessment, re-
gardless of group as literature suggests [37].
Our results highlight the importance of assessing the
capacity of research participants to provide consent. It is
widely held that subjects are deemed competent, unless
it can be proved otherwise, to participate in the in-
formed consent process. If the participants do not fully
comprehend the procedures they are consenting, safe-
guards should be implemented to protect them, but we
argue these safeguards should be tailored capacity-based
not diagnoses-based. The view that addicted individuals
















Fig. 2 MacCAT-CR scales scores in SUD. Abbreviations: MacCAT-CR,
MacArthur Competence Assessment Tool for Clinical Research; SUD,
Substance Use Disorders; NS, Non significant
Table 2 Decisional capacity characteristics
Variable Substance Use Disorders (n = 52) Non psychiatric comparison subjects (n = 50) P Value
Capacity (%) 67.3 84.0 .05 b
MacCAT-CR ( mean ± SD)
Understanding subscale score (range, 0–26) 20.1 (5.2) 23.0 (3.5) <.001a
Appreciation subscale score (range, 0–6) 5.0 (1.4) 5.7 (0.8) .003 a
Reasoning subscale score (range, 0–8) 6.1 (1.8) 6.5 (1.4) .359 a
Expression of a choice subscale score (range, 0–2) 1.8 (0.5) 2.0 (0.2) .159 a
Abbreviations: SD, standard deviation; MacCAT-CR, MacArthur Competence Assessment Tool for Clinical Research
a Mann–Whitney U
b Pearson’s χ2
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virtue of being addicted, would, if accepted, significantly
hinder research on addiction, and hence the develop-
ment and evaluation of new treatments that may benefit
addicted persons. This would not only be a violation of
the principle of justice (equal distribution of the benefits
of research) but it may lead to poorer outcomes for
addicted individuals and society [18]. This approach to
people with SUD raises ethical concerns about respect for
the principle of autonomy. Increased restrictions on re-
search involving persons with SUD, no matter how well
intentioned, may reflect and reinforce stigmatization of
those persons. Beyond the diagnosis, other sets of factors
have been identified as influencing the process capacity
determination: the risk context, and the knowledge and
characteristics of those making the judgment about
decision-making capacity [36, 42]. An evaluator who
places greater value on protecting an individual from po-
tential harm may, for any given risk–benefit scenario, re-
quire a higher threshold of ability than another evaluator
who tends to place on the side of allowing the person to
determine his or her own course. This apparently en-
hanced sensitivity to human subject’s protection in SUD
research may overestimate the vulnerability of SUD re-
search participants.
Assesment of competence must be regarded as risk-
related and task-related: a specific judgement at a specific
moment of the ability of one person to fulfill a concrete
task. The application of this model has implications for
designing a research protocol, especially when standards
for competence are being set [36]. For example, it’s neces-
sary that investigators state a priori judgment of what con-
stituted minimally adequate understanding of a specific
research protocol. The threshold for finding an individual
capable of making a decision should vary depending upon
the risks and benefits involved (i.e., when the stakes are
higher, a higher level of ability is necessary).
As our results has shown, lack of understanding in in-
formed consent process may occur both in clinical
population and in NPCs, so we argue that routine evalu-
ation of decisional capacity in greater-than-minimal-risk







(n = 35) (n = 17)
Age, years (mean ± SD) 42.3 (11.3) 44.9 (11.2) .545a
Women (%) 86.7 13.3 .045 b
Men (%) 59.5 40.5
Marital Status (%) .239 b
Married/cohabiting 75 25
Never married 78.6 21.4
Previous married 54.5 45.5
Living status (%) .041 b
Alone 75 25
With family 75 25
Parents/Institution 55 45
Education level (%) .033 b
Primary 55.3 46.7
Secondary 82.4 17.6
University degree 100 0




Disabled person 81.8 18.2
Psychiatric diagnoses (%) .668 b
Psychotic disorders 55.6 44.4
Mood Disorders 78.6 21.4
Anxiety disorders 62.5 37.5
No psychiatric diagnosis 69.2 30.8
CGI (%) <.006 b
Less than moderately ill 100 0
Moderately ill or more 57.5 42.5
GAF (range, 0–100) (mean ± SD) 70.2 (16.7) 57.6 (8.1) .003 a
Length of illness, years (mean ± SD) 12.9 (10.1) 18.5 (10.5) .056 a
Psychiatric Admissions (mean ± SD) 0.9 (1.5) 1.4 (3.4) .782 a
Therapeutic Community Admisisons
(mean ± SD)
0.26 (0.6) 0.75 (1.1) .058 a
MMSE scores (range, 0–30)
(mean ± SD)
29.1 (1.3) 28.1 (1.4) .007 a




Alcohol + other 68.4 31.6
MacCAT-CR ( mean ± SD)
Understanding subscale score
(range, 0–26)
23.0 (1.9) 15.2 (3.3) <.001 a
Table 3 Comparison of patients with and without capacity to
consent to research (Continued)
Appreciation subscale score
(range, 0–6)
5.4 (1.0) 4.3 (1.5) .008 a
Reasoning subscale score
(range, 0–8)
6.7 (1.2) 5.1 (1.9) .002 a
Expression of a choice subscale
score (range, 0–2)
1.9 (0.2) 1.8 (0.6) .164 a
Abbreviations: SD, standard deviation; CGI, Clinical Global Impression; GAF,
Global Assessment of Functioning; MMSE, Mini-Mental State Examination; THC,
Tetra hidro cannabinol; SUD, Substance use disorders; MacCAT-CR, MacArthur
Competence Assessment Tool for Clinical Research
a Mann–Whitney U
b Pearson’s χ2
Morán-Sánchez et al. BMC Medical Ethics  (2016) 17:3 Page 8 of 10
studies may be reasonable. Such screening is therefore
just as appropriate when patients are physically ill as
when they are mentally ill: there is no evidence which
supports inferring a uniform ability or inability to make
decisions on the basis of a specific diagnosis [43].
Limitations
There are a number of limitations that should be consid-
ered when interpreting the results. First, our study was
carried out in an urban setting and it was restricted to a
limited number of outpatients which may limit the gen-
eralisation of the results. Further research is necessary to
assess our results in other settings and participant
groups. Studies with larger sample sizes would also allow
investigators to conduct multiple-regression analyses
with a greater number of independent variables in order
to confirm all the univariate associations in the logistic
regression model.
A second limitation arises from the cross-sectional
data origin. The results presented here do not allow us
to examine changes in consent-related abilities over
time, nor to identify predictors of change. Consequently,
prospective studies about SUD and capacity to consent
to research should be conducted to identify those people
that may require safeguards tailored to protect their
rights.
Another limitation that should be considered is that
both the non-random nature of the sample and the ab-
sence of other SUD (such as heroine and anxiolytics/
hypnotics use disorders) raise questions about the
generalizability of the results. Future studies should asses
capacity in these SUD.
Conclusions
The findings of our study provide evidence that a large
proportion of individuals with SUD had decisional cap-
acity for consent to research. It is therefore inapropiate
to draw conclusions about capacity to make research de-
cisions on the basis of a SUD diagnosis, because most of
addicted people remain capable of giving autonomous
consent under most circumstances. In the absence of
acute withdrawal or intoxication or advanced cognitive
impairment, we should assume that addicted persons
possess decision-making capacity. Thus, the view that
people with SUD would ipso facto lose decision-making
power for research consent is flawed and stigmatizing.
Institutional Review Boards and investigators should
consider these caveats as they decide which populations
or individual subjects may require more intensive evalu-
ation or further educational efforts to enhance decisional
capacity, especially for greater-than-minimal-risk studies
like our hypothetical study was.
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